Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 560Neoplasms 504Carcinoma, Non-Small-Cell Lung 421Prostatic Neoplasms 331Colorectal Neoplasms 315Lung Neoplasms 284Neoplasm Metastasis 238Leukemia, Myeloid, Acute 222Ovarian Neoplasms 206Pancreatic Neoplasms 196Multiple Myeloma 186Squamous Cell Carcinoma of Head and Neck 141Stomach Neoplasms 140Recurrence 140Brain Neoplasms 139Melanoma 134Carcinoma, Hepatocellular 132Endometrial Neoplasms 128Glioblastoma 126Precursor Cell Lymphoblastic Leukemia-Lymphoma 117Triple Negative Breast Neoplasms 116Hematologic Neoplasms 104Head and Neck Neoplasms 103Carcinoma, Renal Cell 102Urinary Bladder Neoplasms 99Lymphoma 99Sarcoma 96Glioma 96Esophageal Neoplasms 92Uterine Cervical Neoplasms 88

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Classic Follicular Lymphoma × 90 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡